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Background aims. Economic ex vivo manufacture of erythrocytes at 1012 cell doses requires an efﬁciently controlled bio-
process capable of extensive proliferation and high terminal density. High-resolution characterization of the process would
identify production strategies for increased efﬁciency, monitoring and control. Methods. CD34þ cord blood cells or
equivalent cells that had been pre-expanded for 7 days with Delta1 Notch ligand were placed in erythroid expansion and
differentiation conditions in a micro-scale ambr suspension bioreactor. Multiple culture parameters were varied, and
phenotype markers and metabolites measured to identify conserved trends and robust monitoring markers. Results. The cells
exhibited a bi-modal erythroid differentiation pattern with an erythroid marker peak after 2 weeks and 3 weeks of culture;
differentiation was comparatively weighted toward the second peak in Delta1 pre-expanded cells. Both differentiation events
were strengthened by omission of stem cell factor and dexamethasone. The cumulative cell proliferation and death, or
directly measured CD45 expression, enabled monitoring of proliferative rate of the cells. The metabolic activities of the
cultures (glucose, glutamine and ammonia consumption or production) were highly variable but exhibited systematic change
synchronized with the change in differentiation state. Conclusions. Erythroid differentiation chronology is partly determined
by the heterogeneous CD34þ progenitor compartment with implications for input control; Delta1 ligand-mediated pro-
genitor culture can alter differentiation proﬁle with control beneﬁts for engineering production strategy. Differentiation
correlated changes in cytokine response, markers and metabolic state will enable scientiﬁcally designed monitoring and
timing of manufacturing process steps.
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Red blood cell transfusions are one of the most
common clinical interventions worldwide. This pro-
cess is currently supported by approximately 90  106
annual voluntary blood donations each year. However,
thedonation system is increasingly stretched, leading to
demand for a manufactured red blood cell product to
reduce the logistical issues with donor cells. These is-
sues include a projected donor/recipient imbalance in
aging populations, low donor recruitment and trans-
missible disease risk in developing countries, sustain-
ability of immune matched supply to high-demand
patient groups (e.g., patients with sickle cell anemia),
and the (much debated) detrimental effects of storage
on erythrocytes (1). Consequently, there has beenCorrespondence: Dr Robert J. Thomas, Healthcare Engineering Research Gro
Manufacturing Engineering, Loughborough University, Loughborough, LE11 3T
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the production of clinically transfusable red blood cells
from a renewable stem cell source.
Successful protocols to produce late-stage matu-
rity erythroid cells have been developed based on
both umbilical cord-derived hematopoietic stem cell
(HSC) populations and human pluripotent stem cell
populations. An HSC source has been used more
recently to generate an erythrocyte population that
was successfully transfused in a human proof-of-
principle study; the transfused cells underwent ﬁnal
maturation in vivo and persisted for approximately
1 month after transfusion (2). Human pluripotent
stem cell-based approaches have not yet reached the
clinic but are advanced in terms of quality of ﬁnal redup, Centre for Biological Engineering, Wolfson School of Mechanical and
U, UK. E-mail: R.J.Thomas@lboro.ac.uk
ublished by Elsevier Inc. All rights reserved.
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an unlimited quantity of input cell line material
compared with a requirement for repeated primary
sourcing with HSCs. However, the human pluripo-
tent stem cell starting cells have a longer and more
complex path of differentiation and require more
process control to reach a ﬁnal product.
A possible method to overcome the limited mature
lineage yield from primary HSCs would be to increase
proliferation of the early-stage progenitors. Clinical
demand for transplantable HSCs as part of leukemia
treatment regimens has motivated numerous devel-
opments to support early progenitor proliferation,
including novel biologic mediators, such as Notch
ligand Delta1, or chemical mediator approaches, such
as inhibition of the aryl hydrocarbon receptor (4).
Multiple other approaches are at the non-clinical stage,
such as regulation of inhibitory feedback networks
through control of common culture parameters (5).
As the biologic protocols for progenitor prolifera-
tion and myeloid/erythroid differentiation become
better deﬁned, greater attention needs to be paid to the
manufacturing challenges of ex vivo erythrocyte pro-
duction. The challenge, regardless of source stem cell
population, is dominated by a cost of goods issue. A
single unit of blood contains approximately 2  1012
cells, far greater than the quantity required by most
candidate cell therapies. To reach a 10-L ﬁnal pro-
duction volume for a unit of blood, densities on the
order of 1 108cellsmL1 would need to be achieved;
generating 100 units of blood from a 1  106 cell
starting population would require approximately 28
population doublings (PDs). The purity and concen-
tration of cultured product determine the scale and
cost of downstream processing requirements. Appro-
priate manufacturing systems and processes are crit-
ical to delivering sufﬁciently high production densities
and efﬁcient generation of end product per starting
cell material, with economically viable inputs of cul-
ture consumables, facility andmachine time and labor.
Early approaches to these scale-up challenges
focused on suspension culture and differentiation
of HSCs; this step would need to be addressed
regardless of the progenitor source. Agitated bag
systems have been successfully applied (6) and, in
our laboratories, scaled down stirred tank processing
(7). The latter process sustained cell proliferation
beyond densities of 1  107 cells mL1. Proliferative
capacity issues can potentially be addressed through
prolonging culture to increase the number of blood
cells per input cell, although this protracted prolif-
eration appears to reduce the quality of the terminal
differentiation process (6).
Engineering a process to achieve such a high level
of efﬁciency necessarily requires a greater degree of
control, which is contingent on tighter processtolerances; this requires a sufﬁciently high-frequency
and precise characterization of the physical state of the
process (both cell population and environment) to
enable data-driven process modiﬁcations and imple-
mentation of appropriate monitoring and responses.
Such an approach would also facilitate identiﬁcation
of markers that can accurately report the functional
state of the bio-process. High-frequency monitoring is
particularly important for stem cell differentiation
because of rapid changes in the cell population and
consequently its response to the process environment.
It is suggested that a fundamental issue with many
stem cell-based processes is a lack of adequate moni-
toring data throughout the process.
To address these issues, we used two different
HSC populations: directly isolated cord blood CD34þ
cells and CD34þ cells after 7 days of pre-expansion
with Delta1 Notch ligand. The latter population
potentially has production beneﬁts associated with
enhanced progenitor expansion (8). Cells were pro-
ﬁled for differentiation state and metabolite con-
sumption throughout the previously reported erythroid
protocol in a suspension bioreactor (7). We have
identiﬁed unreported patterns in the differentiation
proﬁle, tools with which to manipulate these patterns
and an effective process monitoring marker conserved
throughout all process conditions and input cells. In
light of these, we discuss implications for further
manufacturing development of a blood product.
Methods
Cells
Two different cryopreserved input cell populations
were obtained: (i) mixed donor CD34þ umbilical
cord-derived cells enriched via negative selection
using RoboSep automated cell separator (AllCells,
Alameda, CA, USA) and (ii) umbilical cord-derived
CD34þ cells after 7 days of pre-expansion with
Notch Delta1 ligand in conditions previously
described (9) (provided courtesy of Professor Irwin
Bernstein, Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA, USA).
Bioreactor inoculation and maintenance
The ambr bioreactor (TAPBiosystems, Royston, UK)
is a scaled-down version of a classic stirred tank
bioreactor operating at micro-scale (10e15 mL), us-
ing multiple disposable micro-bioreactors, with indi-
vidual, automated, online monitoring and control of
pH, oxygen gassing, temperature and stir rate. The
system has been validated for 2-L scale-up equivalence
(10). Before cell defrost, ambr vessels were loaded
with 14 mL of medium and stabilized for tempera-
ture (37C), oxygen delivery and pH. Automated
Figure 1. Representative growth characteristics and differentiation proﬁles (assessed by Hb expression and size change) of Delta1 ligand pre-
expanded CD34þ cells and directly isolated CD34þ cells across the culture period. (A) Both cell populations showed similar growth proﬁles in
the bioreactor (accounting for the pre-expansion of the former group). (B) Bi-modal differentiation pattern, conserved under every test
condition, was observed with a Hb peak at day 13 and again at day 22 of culture. The timing was equivalent for both cell types. The magnitude
of the early peak and subsequent trough in Hb expression were greater in the unexpanded CD34þ cells. (C) Cell size changes (ﬂow cytometry
forward scatter) support the bi-modal differentiation events. A signiﬁcant small population is detected at day 13 coinciding with the ﬁrst Hb
expression peak. A split between large and small cell populations exists up to the end of the process. The balance of this split depends on the
originating cell types. The CD34þ cells show a relatively synchronous shift in cell size. Delta1 pre-expanded cells maintain a more mixed
population size throughout the period of day 13e20 and beyond. (D) At day 22 of the process, the cell population can be categorized into
quadrants as large/small size and high/low CD71-expressing populations. The most mature erythroid population, small cells with low CD71
expression, would be expected to synchronize with the high Hb expression at day 13 and day 22 of the process. However, this population is
clearly distinctive only at day 22 suggesting a later state of maturity is achieved in the second peak of differentiation in both input cell pop-
ulations. The percentage of the population in this state is annotated. A representative histogram showing the proportion of cells expressing the
erythrocyte marker, CD235a, that are positive (nucleated) or negative (enucleated) for the nuclear stain Syto16 and a benzidine Wright-
Giemsa-stained micrograph are also shown to illustrate terminal enucleation occurring at this point in the culture. Arrows point to enucleated
cells in themicrograph, and these cells appear in the left peak of the plot (i.e., CD235a expressing and no nuclear stain). An erythrocyte positive
control at equivalent scale is inserted at the top left of the micrograph for comparison. (E) To determine the response of the two differentiation
peaks to a process intervention designed to enhance erythroid differentiation, supplementation with SCF and dexamethasone was stopped after
11 days of culture. This caused sustained CD235a expression across the trough between the two differentiation events and a shortened trough
in Hb expression. The bi-modal pattern of differentiation was conserved in both input cell populations.
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Figure 1. (continued).
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Aldrich, Dorset, UK) were made every 48 h. Culture
pHwasmaintained by automated sodium bicarbonate
(20 mL of 1 mol/L solution; Sigma-Aldrich) additions
at 2-h intervals (if required) and regulated carbon di-
oxide gassing. Impeller speed was 450 rpm.
Input cells were thawed and inoculated to the pre-
conditioned bioreactor. Cells were cultured with a
control protocol comprising 1E5 cells/mL in Iscove’s
modiﬁed Dulbecco’s medium with GlutaMAX-I
(Invitrogen, Paisley, UK) supplemented with cytokines
and reagents for erythroid cell proliferation and differ-
entiation (R&D Systems, Abingdon, UK, unless
otherwise stated): bovine serum albumin 1% (Sigma-
Aldrich), insulin 10mg/mL (Sigma-Aldrich), transferrin
330 mg/mL, stem cell factor (SCF) 100 ng/mL,
insulinlike growth factor-I 40 ng/mL, interleukin-
3 5 ng/mL, erythropoietin 3 IU/mL, lipids 40 mg/mL
(Sigma-Aldrich), dexamethasone (Dex) 1 mmol/L
(Sigma-Aldrich), penicillin-streptomycin 1% (Invi-
trogen), Pluronic F-68 0.10% (Sigma-Aldrich).
Replacement of culture medium was conducted
through centrifugation and re-suspension of cells at
1E5/mL in fresh medium every 2e3 days.
In addition to these control culture conditions, a
range of cell culture variables reported to affect
proliferation and differentiation were explored,
including culture densities (4E4 to 1E6 cells mL1),
5% oxygen (11), low pH (7.2) (12) and addition or
concentration changes of supplementary mediators:
vascular endothelial growth factor (10 ng/mL)/insu-
linlike growth factor-II (250 ng/mL) for initial 6 days(13), 5% Plasmanate supplement (13), 1 IU/mL
erythropoietin (low), no lipids (14), no supplemen-
tation of SCF/Dex after 11 days (13).
Culture analysis
Cells and culture medium were sampled for ofﬂine
analysis at each exchange of culture medium.
Metabolite analysis was conducted using a Nova
BioProﬁle FLEX (Nova Biomedical, Runcorn, UK)
in accordance with manufacturer’s instructions and
speciﬁc cell consumption rates calculated as follows:
Specific consumption ¼ CNi * f½EXPðr * ½TTiÞ
 1=rg
where r ¼ [ln(CN/CNi)]/(T  Ti) and Ti ¼ time at
start of culture period, T ¼ time at end of culture
period,CNi¼ cell number atTi andCN¼ cell number
at T.
Online cell counting and viability (trypan blue
membrane integrity) was conducted (Vi-Cell; Beckman
Coulter, Inc, Brea, CA, USA) to calculate cell seeding
densities. Cell apoptosis or necrosis was also mea-
sured using Guava Nexin Reagent (annexin V bind-
ing and 7-amino-actinomycin D penetration) and
Guava ﬂow cytometer (Millipore, Watford, UK)
per manufacturer’s protocol. PDs were calculated as
follows:
PDs ¼ f½LOG10ðCN=CNiÞ * 3:33g=ðT TiÞ
Cell samples were taken for ﬂow cytometry anal-
ysis of erythroid lineage markers. Antibodies were
1110 K. E. Glen et al.pre-conjugated CD235a-PE, CD71-FITC, CD34-
PE, CD45-PE, CD117-PECy5, fetal hemoglobin
(Hb)-PE (BD Biosciences, Oxford, UK) and appro-
priate isotype controls. Cell samples were washed in
ﬂow cytometry staining buffer (R&D Systems) and
incubated with antibody as per manufacturer’s in-
structions for 30 min at 4C. Cells were washed twice
in ﬂow cytometry staining buffer and ﬁxed with 2%
paraformaldehyde (Sigma-Aldrich). The fetal Hb
staining was pre-ﬁxed and permeabilized with BD
Cytoﬁx/Cytoperm kit (BD Biosciences) per manu-
facturer’s protocol. A Guava Flow Cytometer was
used for analysis, and geometric mean (Gmean) values
were used to determine cell expression. The Gmean
was calculated as the average between the start and
end of any given culture period.Statistics and modeling
Minitab (Minitab Inc, State College, PA, USA) was
used to conduct best subset regression, statistical
comparisons (analysis of variance) and correlation
analysis (Pearson correlation coefﬁcient). Where
Pearson values are compared, a Fisher r-to-z trans-
formation was calculated and applied to assess the
signiﬁcance of the difference between correlations.Results
Growth and differentiation trends
Initially, we sought to characterize the time proﬁle of
erythroid expansion and differentiation in scalable
suspension culture format from two different umbilical
cord hematopoietic progenitor populations: directly
isolated CD34þ cells and CD34þ cells that had been
pre-expanded for 7 days with Delta1 Notch ligand.
Frequent growth and phenotype measurements
showed that both input cell populations differentiate
toward a late-stage hemoglobinized erythroid pheno-
type at similar rates (Figure 1A,B). Both cell
populations also showed a bi-modal erythroid differ-
entiation pattern; Hb expression peaked in synchrony
with the detection of a small cell size sub-population
after approximately 2 weeks and 3 weeks of culture
(Figure 1B,C). The small cells in the second differ-
entiation peak contained a CD71low expressing cell
population indicating late-stage mature erythrocytes
and demonstrated enucleation observed by micro-
scopy and CD235a/nuclear co-staining (Figure 1D).
Although the gross trends in maturation were com-
parable between input cell populations, the two dif-
ferentiation events were signiﬁcantly more distinct in
the directly isolated CD34þ population relative to the
cells that had been pre-expanded with Delta1 Notch
ligand. This is evident in both the reduced magnitudeof the dip in Hb expression between weeks 2 and 3
and the lower synchronicity of cell size distribution
changes throughout the process in the Delta1 pre-
expanded cells.
A total proliferative advantage of Delta1 pre-
expanded cells was observed relative to the primary
CD34þ sourced cells indicating the potential for
increased yields through early progenitor manipula-
tion. However, there is clearly signiﬁcant sample-
to-sample variability [previously reported progenitor
makeup of cord blood (15)] (Figure 1, Table I).
To determine the response of the bi-modal dif-
ferentiation peaks to a previously reported method
for enhancing late stage differentiation [SCF and
glucocorticoid withdrawal (13)], supplementation
with these cytokines was stopped after 11 days of
culture, before the initial differentiation. In this
instance, differentiation was enhanced, assessed by
Hb and CD235a expression, in both input cell types.
The trough in expression of the markers over the
third week of culture also was reduced in magnitude
and shortened, most notably in the CD34þ input cell
population (Figure 1E).Relationship between culture history and growth rate
(directly isolated CD34þ cells)
Identifying process markers that are effective at
predicting the functional state of a cell population in a
bio-manufacture process is important to enable
meaningful process monitoring for precisely timed
process interventions. These process markers are
of critical importance in stem cell differentiation pro-
cesses where cell populations and their bio-manufac-
ture demands change rapidly. As described in the
methods section, different progenitor cell populations
were exposed to a range of different physical and
cytokine conditions to cause differing rates and levels of
erythroid differentiation; this generated a data set that
we could use to identify conserved relationships over a
wide range of operating conditions.
Cell growth rate in the bioreactor was the initial
target for modeling because it is a primary bio-
process functional output. Given that the cells were
in an erythroid progenitor tailored expansion and
differentiation medium, the maturity of the cell
population on the erythroid lineage commitment
pathway was proposed as the key determinant of
the cell responsiveness to the growth factor cocktail
and the cell growth rate. The corollary to this is
that the number of PDs the cells have passed
through (i.e., the more responsive they have been)
is likely to be a primary determinant of population
maturity.
In support of this hypothesis, a strong relation-
ship was identiﬁed between the PD rate of the cells
Table I. Notch cells expansion and primary CD34þ expansion.
Notch cells
expansion 1
Notch cells
expansion 2
Notch cells
expansion 3
Primary CD34þ cells
expansion 1
Primary CD34þ cells
expansion 2
Notch expansion phase (PD rates) 6.83 6.65 7.16 e e
Suspension expansion (PD rates) 7.73 9.84 8.54 13.9 11.4
Total (PD rates) 14.56 16.67 15.7 13.9 11.4
Total (fold expansion) 2.4E4 1.04E5 5.3E4 1.6E4 2.7E3
Erythrocyte manufacturing process characterization 1111and cumulative population doublings (CPDs). The
relationship between CPDs and PD rate, particularly
in the later phase of culture, could be strengthened if
we calculated an adjusted cumulative population
doubling (ACPD) ﬁgure that inﬂated CPDs to
account for cumulative cell death within cultures
(assessed by percentage of trypan blue positive).
A least-square ﬁt was used to identify a cell death
co-efﬁcient to generate the best relationship with PD
rate: ACPD was deﬁned as CPDs þ 0.7 CD. Non-
linear regression was used to ﬁt a function to the
relationship between ACPD and PD per day
(Figure 2A).
Regression equation (1):
R ¼ 0:2811þ 0:3737 * M 0:03159 * M * * 2
þ0:000680 * M * * 3
S ¼ 0:13;R  Sq ¼ 87%
ðcoefficient P values < 0:001ÞFigure 2. The relationships between cell PDs/day and both historical cum
operating conditions (dot per bioreactor). (A) Cumulative population d
with the average PD rate (Rsq ¼ 88%). It was considered to be a goo
excellent correlation with the adjusted cumulative PDs relative to a range
effective alternative indicator of functional state for the cultures. (C) A
lationships has a good correlation with actual growth rate for cells underg
CD34þ cells (Rsq ¼ 76%). (D) This predictive ability is substantially ret
cells previously expanded with Delta1 ligand (Rsq ¼ 62%).where R is the growth rate estimate (PDs per day) and
M is the maturity estimate (ACPD).
The relationship between PD rate and ACPD
was stronger than the relationship with culture
duration, suggesting that the cell population
response was determined to a greater degree by its
proliferation history rather than culture time and
that ACPD could be a useful metric for predicting
proliferative state of the culture under variable
operating conditions.
Relationship between phenotype and growth rate
Calculation of CPD or ACPD depends on the
availability of process history data. Such data might
not be available during production. Error accumu-
lates throughout the process, and a single measure-
ment with a large error (or one that could not be
made at all) has an effect on the accuracy of all
subsequent calculations. Although ACPD is both
an intuitively meaningful parameter representingulative proliferation and CD45 marker expression over a range of
oublings adjusted for cell death (ACPD) had a strong relationship
d measure of population maturity. (B) CD45 expression had an
of other relevant markers (R  Sq ¼ 94%) making this marker an
CD45-derived growth rate prediction determined from these re-
oing erythroid proliferation and differentiation from freshly isolated
ained when applied to an alternative cell input population, CD34þ
Table II. Range of speciﬁc metabolite consumption and
production rates observed over the proliferation and differentiation
process.
Mean SD Minimum Maximum
Glutamine/cell/day (Delta1) 4.19 2.22 0.37 10.64
Glucose/cell/day (Delta1) 0.91 0.47 0.00 1.92
Ammonia/cell/day (Delta1) 1.90 1.20 0.70 7.27
Glutamine/cell/day (CD34þ) 2.27 4.22 0.00 36.47
Glucose/cell/day (CD34þ) 1.56 1.86 0.00 13.15
Ammonia/cell/day (CD34þ) 0.96 1.22 0.08 8.93
Ranges and mean values are shown (glutamine E6 mmol/cell/day,
glucose E6 g/cell/day, ammonia E6 mmol/cell/day).
1112 K. E. Glen et al.population maturity and a good predictor of a key
physiologic parameter (growth rate), measures of
population maturity that do not require historical
data have greater practical robustness from a bio-
manufacturing perspective. We investigated if any
directly measured marker or marker combinations
had a robust relationship with ACPD that could be
combined with the known non-linear functional ef-
fect of ACPD to predict culture behavior.
We conducted multiple linear regression to
determine any linear relationships between the
ACPD and themarker proﬁle of the cells measured by
mean population expression of CD34, CD71,
CD235a, CD45, CD117 (SCF-R) and Hb. CD45
was the best independent predictor of ACPDs with a
remarkably strong correlation (R  Sq ¼ 94%, P 
0.001) (Figure 2B). Combination with additional
markersdidnot increase the strengthof the relationship.
Regression equation (2):
MCD45 ¼ 26:31 10:23 Log10 FCD45
S ¼ 1:23; Rsq ¼ 94%
ðcoefficient P values  0:001Þ
where MCD45 is an alternative directly measured
estimate of the functional state of the population,
previously measured by ACPD, and FCD45 denotes
mean ﬂuorescence for the marker CD45.
The relationship between CD45 and ACPD can
be combined with the non-linear relationship deﬁned
between ACPD and growth rate to provide CD45
monitoring of the growth rate of the cell population
during the erythroid differentiation process. This is
demonstrated by a linear correlation of the predicted
population growth rate (derived from substituting
MCD45 into regression equation 1) and the actual
population growth rate (R  Sq ¼ 76%, P  0.001)
(Figure 2C).
Relationship of phenotype to growth rate: robustness for
cells pre-expanded with Delta1 Notch ligand
To test the robustness of the relationship determined
with directly isolated CD34þ cell data, we used the
Delta1 expanded HSC population. These cells had
been exposed to an alternative expansion regimen,
Delta1 Notch ligand, and are shown to follow a
different differentiation proﬁle. ACPD and MCD45
maturity values were both used to calculate the pre-
dicted population growth rate using regression
equation 1. MCD45 (R  Sq ¼ 62%, P  0.001)
provided a better correlation of real growth rate than
the direct ACPD derived value (R  Sq ¼ 51%, P 
0.001) (signiﬁcance of difference between correla-
tions P ¼ 0.1) (Figure 2D). This improved predic-
tion with CD45 is hypothesized to be due to thecumulative error associated with ACPD. The strong
relationship between CD45 and ACPD and the
ability of the marker to predict proliferative rate of
culture over diverse operating range and input cells
suggests robustness that could be useful for moni-
toring process state in erythrocyte production.
Establishing relationships between phenotype and
metabolic activity
Given that the growth rate of the cells could be
predicted by measures of cell population maturity,
we proposed that other bio-manufacture critical at-
tributes, such as metabolic behavior, could be pre-
dicted using the same tools. We investigated the
relationship of ammonia production and glutamine
and glucose consumption per cell with ACPD for
both input cell populations.
Metabolic activityper cell variedsubstantially across
the differentiation and expansion process (Table II).
However, therewere distinctive and conserved patterns
in both processes relative to the proliferative history of
the cells. The cultures had a peak of metabolic activity
(glucose use and ammonia production) after approxi-
mately 11 ACPDs followed by a substantial decline to
13 of 14 ACPDs that approximate the bi-modal dif-
ferentiation pattern (Figure 3). Although the pattern
was conserved for either input cell source, thedrop from
a high to low metabolic state was more pronounced in
the directly isolated CD34þ cells, compared to those
pre-expanded with Delta1 ligand; this mirrors the
greater separation of the bi-modal differentiation pro-
cess in the former cells (Figure 3).
To understand the relationship between the dif-
ferentiation cycle and speciﬁc metabolic activity
further, we withdrew SCF and Dex at day 11 of
culture (previously established as a means of
enhancing the pace of late-stage erythroid differen-
tiation). Early withdrawal of these growth factors led
to earlier and higher levels of differentiation
(CD235a, Hb) and brieﬂy enhanced proliferation
(Figure 4A,B). After approximately 11 ACPDs, the
more rapidly proliferating and maturing cells showed
a suppression of glutamine consumption and
Figure 3. Cells processed under multiple different conditions from fresh CD34þ cells (A) or from Delta1 ligand expanded CD34þ cells (B)
show characteristic patterns of nutrient consumption related to the differentiation cycle (dot per bioreactor). The differentiation process,
assessed by Hb accumulation, progresses for 11 ACPDs, after which there is a loss of maturity (CD34þ) or a hiatus in the progression
(CD34þ Delta1 Notch ligand expanded cells). This break in the progress of differentiation is associated with an equal duration decline in
metabolic activity measured by glucose consumption per cell to ACPD 14. This is also seen in production of ammonia per cell for the fresh
CD34þ cells (in which the differentiation pattern is most pronounced) but was not observed in the Delta expanded cells.
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effect on glucose consumption was not observed.
The effect of higher growth and lower nutrient
consumption appears counter-intuitive. We com-
pared the rate of cell proliferation with glutamine
consumption using data from across the growth
period. A linear relationship between glutamine con-
sumption and growth rate was present when SCF and
Dex supplementation was maintained and differenti-
ation was relatively suppressed. However, withdrawal
of the growth factors led to a high proliferative and low
metabolite consuming state and loss of linear rela-
tionship (Figure 4E). This ﬁnding strongly indicates
that both rate of proliferation and differentiation status
have separate and potentially confounding relation-
ships with metabolic behavior, and culture metabolic
demand would be a function of both properties.
Discussion
The objective of these studies was to provide a high-
resolution characterization of the erythroid prolifer-
ation and differentiation process to improve designand monitoring of suspension scale-up and manu-
facture. The data indicate cyclic patterns in differ-
entiation and metabolic behavior that would need to
be addressed in a manufacturing scenario. The data
also identify rapid process change and robust pre-
dictive process measurements that inform the extent
of process monitoring that would be required to
optimize and control an erythrocyte production
process.
Expansion and proliferation characteristics: implications
for manufacture
The two temporally distinct differentiation events from
the CD34þ cord cell population suggest at least two
levels of erythroid progenitor maturity within the initial
cell population. The median frequencies of three
distinct progenitor sub-populations with erythroid
potential in the CD34þ cord blood compartment have
been reported previously: HSCs 6.6%, common
myeloid precursors 3.2%, megakaryocyte erythroid
precursors 0.12% (15). The early differentiation peak
observed in the bioreactor is likely to reﬂect the latter
Figure 4. To characterize further the link between the differentiation cycles and the metabolic behavior of the cells, we withdrew Dex and
SCF supplementation after 7 days of culture (triplicate bioreactors individually shown). This had the effect of changing the rate of early
differentiation measured by CD235a (A) or Hb (B) with respect to proliferation at approximately 12 ACPD (circled). Removal of Dex and
SCF and more rapid differentiation reduced the ﬁrst peak in glutamine consumption (C) and ammonia production (D) per cell. (E) There
was a linear relationship between growth rate and glutamine use while SCF and Dex were present; this relationship was non-linear when
growth factors were removed, suggesting a change in metabolic demand relative to activity.
1114 K. E. Glen et al.two progenitor populations rapidly responding to the
interleukin-3/erythropoietin-rich culture environ-
ment, corresponding to a 2-week single-wave expan-
sion/differentiation life cycle for these committed
progenitors. The later maturing population is likely to
be derived from the HSC compartment, which would
take longer to become responsive to the erythroid
progenitor targeted cytokines. The wide variability in
progenitor distribution among donors provides an
explanation for the variable sample-to-sample prolif-
erative capacities we have reported (15). The impli-
cation that a relatively small proportion of the CD34þ
compartment contains cells with erythroid potential
would be a signiﬁcant cause of the lag phase at the start
of culture.
The Notch ligand, Delta1, has complex devel-
opmental effects. It is primarily reported as a regu-
lator of hematopoietic precursors, inhibiting myeloid
differentiation, enhancing precursor expansion
including rapidly re-populating cells and promoting
T-cell and inhibiting B-cell development (8). This is
the probable explanation for the Delta1 pre-culturedcells showing a sustained expression of erythroid
markers and small cells between the two differenti-
ation events (i.e., a delay in differentiation of some of
the committed progenitors through the third week of
culture). It would also explain any proliferative
beneﬁt of the Delta1 pre-culture protocol.
The different differentiation proﬁles of the
directly isolated or Delta1 ligand-treated CD34þ
cells suggest different approaches to harvest of
mature product. The continual maintenance of high
Hb expression over the ﬁnal week of Delta1 cell
culture suggests multiple high-yield harvest points
could be carried out over the period to take advan-
tage of the increased proliferation or delayed differ-
entiation of the early maturing cells, relative to two
batch harvest points in the directly isolated CD34þ
cells. However, the harvest frequency and conse-
quent yield implications cannot be fully speciﬁed
without further understanding the longevity of
mature cells in the bioreactor environment and the
effect of maturing cells on the immature proliferating
population.
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An accurate measure of functional position in
the blood production process is critical for timely
process control, such as cytokine supplementation
changes, or product harvest and puriﬁcation. In a
large-scale system, such measurements dictate bio-
process interventions, downstream processing re-
quirements and potentially upstream initiation of
further batches. Mapping of variable process inputs
onto consistent process outputs is enabled through
incorporation of process analytic technology and
implementation of control loops, an approach
increasingly favored by regulatory agencies (16).
Informed choice of markers and associated
measurement systems for process analytic technol-
ogy and process control require knowledge of the
sensitivity of the relationship between process
function and various process markers. Deﬁnition of
stem cell populations as categorically positive or
negative for surface and intracellular markers is still
widely applied to assess process quality (17); this is
partly due to uncertainty regarding the functional
signiﬁcance of higher resolution measurements and
the challenge of standardizing among laboratories.
However, these metrics can reduce focus on lower
expressed markers that provide equally signiﬁcant
but lower magnitude shifts in expression with less
categorical distinction between populations. A
categorical, two-population classiﬁcation inevitably
has maximum sensitivity when the population dis-
tribution is centered at the level of the population
divide; this is arbitrary, and there is no evidence to
suggest this maximum sensitivity is aligned to
maximum functional effect, where measurement
sensitivity needs to be greatest. Markers that are
functionally informative for the ﬁnal product are
not always informative for earlier process control.
The predictive utility of CD45 demonstrated
here is a good example; it is a low expressed non-
erythrocyte marker that nonetheless provides
the best functional tracking of cell population
proliferative state for the erythrocyte production
process.
The risk of higher resolution process measure-
ment is identiﬁcation of phenomena that are difﬁcult
to interpret from a product quality perspective.
Although erythrocyte markers such as Hb and
CD235a responded in a qualitatively similar manner
to process changes, quantitative responses were of
different relative magnitude. When such differences
are observed, a product developer may have the
challenge of explaining the functional and safety
implications and incorporating necessary changes
into process development and validation.Models for process control
Deﬁning a stem cell population as a series of discrete
compartments that evolve on a probabilistic basis has
been used to develop population balance equations
for stem cell differentiation that can be combined
with temporal proﬁles of the culture environment to
generate predictive models (18). Such models, if
sufﬁciently broad and predictive, have evident value
for controlling a manufacturing process; the model
complexity required to achieve this value would
depend primarily on the number of signiﬁcantly
functionally distinct cell compartments and their
sensitivities to the process environment.
A small panel of predictor markers would deﬁne
a limited bio-process operating space. A smaller panel
requires greater a priori knowledge of process opera-
tion and incurs the risk of being out of an expected
process space. Conversely, an increasing number of
markers, or strong mechanistic basis, would allow the
prediction of process performance over a wider pro-
cess space, although for both diminishing return in
precision and increasing cost. This is a cost-to-risk/
beneﬁt decision required to determine monitoring
requirements of a stem cell product manufacturing
process. The process reported covered a broad range
of operating conditions, including tests against dif-
ferent input cells, to increase conﬁdence in robustness
of observed relationships.
There is a mechanistic argument that CD45
expression would be associated with proliferative rate;
CD45 expression decreases as the highly erythropoi-
etin sensitive and proliferative burst-forming unit
erythroid cell population changes to a colony-forming
unit erythroid cell population and through normoblast
toward terminal maturation. This ﬁnding provides
mechanistic conﬁdence in the statistical relationship
observed. It is possible, particularly later in theprocess,
that an attribute of a small proportionof the population
is predicting the behavior of the bulk population. The
robustness of any such predictive relationship would
be limited to a restricted set of operating conditions; if
a greater operating space is anticipated, or this process
functionneeds tobepredictedwith greater precision to
control quality, additional cell or process predictors
would need to be developed.
Different functional outputs would require
different levels of complexity and precision in model
terms based on control requirements (process toler-
ance) and control capability (capability to maintain
in given operating space)—hence the disparity
between the ability to predict proliferation from
markers compared with metabolic state. There is
early recognition that homeostatic metabolic path-
ways could play key roles in differentiation and by
implication be key control parameters in ex vivo
1116 K. E. Glen et al.differentiation (19). However, the linear decline of
CD45 expression throughout the process is clearly
not appropriate to establish a simple relationship
with the cyclic changes in metabolic activity.
Although the qualitative metabolic state (high or low)
of the process could be estimated from the ACPD or
CD45 expression of the cells, it would be preferable
to establish a measure of process state that could
directly and quantitatively inform on the functional
metabolic status of the population.
The parallels in the differentiation and metabolic
activity patterns strongly suggest that markers of late
stage differentiation (Hb, CD235a) would be good
candidates to allow such direct predictions. Howev-
er, although such relationships were investigated,
those that existed were not conserved across the
whole process. For example, a linear negative cor-
relation exists between ammonia production and
CD235a expression but only if the two lowest
ammonia production periods are excluded (where
very low production per cell occurs across a relatively
wide range of CD235a expression). We suggest that
this inability to predict directly metabolic state
robustly from cell markers is due to (i) the substantial
and rapid shifts in marker phenotype and metabolism
observed over the process bridging measurement
periods, (ii) insufﬁcient deﬁnition of cell population
to classify metabolic state fully and (iii) key de-
terminants of metabolism, such as growth rate,
changing their relationship with metabolic behavior
as the cells differentiate. This situation potentially
demands higher measurement frequency to deﬁne
relationships in periods of critical change; the data
presented here indicate target areas where measure-
ment and monitoring resolution could be economi-
cally focused. It appears likely that a relatively
high-frequency and complex deﬁnition of population
differentiation state and proliferative state will be
necessary to elucidate these relationships fully.
In conclusion, models that can accurately predict
bio-process behavior from simple measurements are
necessary to monitor and control production of
complex cellular therapies. These models may
become a regulatory necessity or at least greatly
facilitate development, but they can be challenging to
identify. A red blood cell product is likely to be
particularly challenging because of the production
efﬁciency required for economic manufacture and
the complex population dynamics that underlie
aggregate process behavior. CD45 is identiﬁed as a
marker to monitor progress through an erythroid
expansion and differentiation process and generate
quantitative predictions of process function, with
ACPDs as a high-value secondary measure if marker
data are unavailable. We have also identiﬁed com-
plex cyclic behavior of cells with regard to functionalphenotype; such behaviors would need to be
accounted for and monitored in a ﬁnal optimized
manufacturing system.Acknowledgments
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